Treatment of Early Breast Cancer
description
Transcript of Treatment of Early Breast Cancer
Treatment of Early Breast Cancer
Frances Wright MD MEd FRCSC
Objectives
• imaging & diagnosis
• historical overview of surgical treatment
• current practice– breast surgery– axillary staging
Radiologic Work-up
• Common– Mammogram– Ultrasound
• Good for young women• Usually targeted
• Uncommon– Galactogram– MRI
Mammogram
Some cancers are not found until they reach this size
A mammogram can find cancer when it is only this size
www.obsp.on.ca
Benefits of Mammogram
Survival and Stage of Breast Cancer
Mammogram X-ray of the Breast
• No screening tool 100% effective
• 85-90% of all breast cancers in women > 50 can be identified on mammogram
Mammograms and Cancer
Ultrasound of Breast Cancer
Magnetic Resonance Imaging
MRI
• Advantage– Not affected by breast
density– Can identify occult
disease
• Disadvantage– Dependent on who does
the imaging– Sensitive, not very
specific– Need MRI biopsy
capability
Breast MRI – Screening…
• Who should get ?– Screening - evidence
• BRCA mutation carriers• Untested 1st degree relatives of carriers• Family history of hereditary cancer syndrome;
risk > 25%
– Screening – no good evidence • Prior chest radiation before age 30 (Hodgkins)• Some women with LCIS/atypia
MRI for Surgeons
• Treatment Planning – 3% of contralateral breast cancers are occult to
physical exam/ mammo (Lehman 2007)– Occult primary with axillary mets– Paget’s disease of the nipple– Invasive lobular carcinoma – Extent of disease work up– Evaluation of residual disease
Breast Imaging Reporting & Data Systems = BIRADSInterpretation Risk Ca
0 Incomplete assessment
1 Negative 0.05%
2 Benign 0.05%
3 Probably benign 2%
4 Suspicious 15 - 50%
5 Highly suspicious 95 - 99%
6 Known cancer 100%
Imaging
• BIRADs classification
1
2
3 5
4
Needs biopsyNo action
The work-up: Pathology
• Core needle biopsy– Gives more information – – type of cells – invasive vs. non-invasive
• Fine needle biopsy – not done as much now– Malignant vs. not malignant– Rule out cyst
• Excisional biopsy - uncommon now
Ductal carcinoma in situ
Invasive ductal carcinoma
Pathology: Ductal Carcinoma in situ and Invasive ductal Carcinoma
No lymph node involvement
Potential lymph node involvement
• There must be clinical, radiologic and pathologic agreement (concordance) in diagnosis
• If one doesn’t fit – consider surgical excisional biopsy
The evolution of breast surgery
• Halsted 1852 - 1922 • tumour begins small• systematic progression
to surrounding tissues
• involvement of lymphatics leads to distant spread
• local control = cure
The evolution of breast surgery
• Halstedian principles• radical mastectomy
– Breast, pectoralis major and minor and axillary tissue
The evolution of breast surgery
• Bernard Fisher • breast cancer systemic
at onset• surgery impact is local• lumpectomy + RT =
mastectomy
The evolution of breast surgery
• “Fisherian” theory• breast conservation
The evolution of breast surgery
Halstedian principles
radical mastectomy
versus
“Fisherian” theory
breast conservation
Breast conservation
• removal of tumour with a margin of normal tissue • post-operative radiation to reduce local recurrence
rates• suitable for clinical stage I-II tumours (< 5cm, mobile)• acceptable cosmetic outcome• equivalent survival to mastectomy
• higher local recurrence rate 7-8% vs. 5%
Mastectomy
• large or multicentric tumours• unacceptable cosmesis, small breast : tumour ratio• persistent positive margins with conserving surgery• contraindication to radiation• patient preference
Surgical Treatment of Early Breast Cancer
Breast
Breast conservation
or
Mastectomy
Axilla
Sentinel Node Biopsy possible axillary dissection
or
Level I/II axillary dissection
Axillary Surgery
• axillary status most significant prognostic indicator• role in determining need for adjuvant therapy• provides local control if nodes involved with tumour• controversial survival benefit
Axillary Lymph Node Dissection
• associated morbidities– decrease range of motion, sensory defects, pain– nerve injury– lymphedema of ipsilateral arm (10-15%)
• majority of women node negative• no benefit from removal of negative nodes
Likelihood of having lymph node involvement
Diameter of primary tumour
Percent with positive axillary nodes
0.5 - 0.9 cm 21 %
1.0 - 1.9 cm 33 %
2.0 – 2.9 cm 45 %
3.0 – 3.9 cm 55 %
4.0 – 4.9 cm 60 %
> 5.0cm 70 %
Carter 1989
The sentinel node for breast cancer
• Cabanas 1977 - penile cancer and inguinal nodes
• Morton 1992 - melanoma
• Krag 1994 - isotope in breast cancer
• Guiliano - blue dye in breast cancer
• Albertini - blue dye and isotope
Sentinel node concept
• first node or nodes in the draining nodal basin most likely to harbour metastases
• status of the sentinel node reflects the status of the entire nodal basin
• if found to be negative, no further axillary nodes removed
• enables staging with less morbidity
tumour
Radioisotope +/-Blue Dye
radioactivity
blue dye
Pathological evaluation
• usual evaluation is bi-valve of 10 - 20 nodes • retrieval of fewer nodes (1-3) allows more extensive
evaluation– H & E multiple sections – immunohistochemical staining (IHC)
– No accepted standard
Sentinel node biopsy for who?
• small invasive T1 - T2 tumours • clinically node negative• contraindicated in
– locally advanced or inflammatory • Not as accurate
– prior lumpectomy– prior ALND
Sentinel node biopsy by whom?
• specialized multidisciplinary technique involving surgeon, nuclear medicine and
pathology• surgeons should be familiar with risks/benefits and
perform breast surgery routinely• recommended surgeons have performed at least 20
cases with “back up” axillary dissection first• should have a localization rate > 90%• should have false negative rate < 5%
Sentinel Node Biopsy - evidence?
• multi-institutional validation study using radioisotope1
• single institution series using blue dye 2
• over 60 other observational series reporting similar results
• one randomized control trial to date with 46 mo f/u demonstrating no difference in adverse events & less morbidity 3
1Krag et al. NEJM 1998; 339(14):941 - 9462Guiliano et al. Ann Surg 1994; 220:391- 4013Veronesi et al. NEJM 2003; 349(6):546 - 53
Sentinel Node Biopsy - evidence?
• two large multicentre trials recently completed accrual– NSABP 32 & ACOSOG Z0010
– ACOSOG Z0011 accruing (SLN node positive)
• objectives:– determine local recurrence and survival in women
undergoing sentinel lymph node biopsy only – determine morbidity associated with sentinel
lymph node biopsy
Breast Cancer Treatment in the 20th Century:Quest for the Ideal Local-regional Therapy
1900 2000
Radical Mastectomy
Extended Radical Mastectomy
Modified Radical Mastectomy
Lumpectomy
BC + RT
Ax LND
BCT + RT
Sentinel Node BiopsyI D E A L T H E R A P Y
1950 Radiation
Overtreatment
Summary
• Evolution of breast cancer surgery for more to less
• More and more specialized
• Less morbidity for patient